Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
Lipella Pharmaceuticals (Nasdaq: LIPO) announced the completion of its first Site Initiation Visit (SIV) for the Phase 2a trial of LP-310, targeting Oral Lichen Planus (OLP). The trial, starting in mid-2024, will involve 24 adult subjects across five U.S. sites. LP-310, a proprietary liposomal-tacrolimus oral rinse, will be tested for safety, tolerability, and efficacy at doses of 0.25 mg, 0.5 mg, and 1.0 mg. The study addresses the unmet need for an FDA-approved OLP treatment and is expected to conclude in mid-2025. Lipella's CEO and CMO expressed optimism about providing a potential treatment for the 6 million Americans suffering from OLP.
- Completion of Site Initiation Visit (SIV) for Phase 2a trial of LP-310.
- Patient recruitment underway for the trial starting in mid-2024.
- Trial involves 24 subjects across five U.S. sites.
- LP-310 to be evaluated for safety, tolerability, and efficacy.
- Potential treatment for Oral Lichen Planus (OLP) with no FDA-approved therapies.
- Study to conclude in mid-2025, addressing significant unmet medical need.
- CEO and CMO express strong optimism and readiness for trial commencement.
- The trial is still in Phase 2a, indicating a long road ahead before potential approval.
- Estimated conclusion date in mid-2025 could delay any marketable product.
- Uncertainty remains around trial outcomes and FDA approval.
Insights
The initiation of Lipella Pharmaceuticals' Phase 2a trial for LP-310 signifies a pivotal moment for the company and the broader biotechnology field. The trial aims to address Oral Lichen Planus (OLP), a condition affecting around 6 million Americans and currently lacking FDA-approved treatments. The formulation being tested, liposomal-tacrolimus (LP-10), is notable for its potential to minimize systemic toxicity, a common concern with tacrolimus. A multicenter approach enhances the robustness of the data, helping to ensure that the findings are generalizable across different patient populations. If successful, LP-310 could significantly improve the quality of life for OLP patients and position Lipella as a leader in this niche but critical therapeutic area.
From a market perspective, the successful initiation of a Phase 2a trial for LP-310 is an encouraging development for Lipella Pharmaceuticals. The unmet need for effective OLP treatments presents a substantial market opportunity. The trial's dose-ranging and multicenter design increases the likelihood of generating meaningful data, which can support future regulatory submissions. Investors should note that while the trial is in early stages, positive outcomes could lead to a significant revaluation of Lipella's stock, given the high unmet need and the potential for first-mover advantage in the OLP treatment market.
For investors, the completion of the Site Initiation Visit (SIV) is a key milestone, often seen as a sign that the trial is progressing as planned. This can reduce some of the immediate risks associated with clinical trials, such as regulatory delays. However, it's important to remain cautious—Phase 2a trials are still early-stage and the outcome remains uncertain. The financial implications hinge on successful trial results, which could lead to partnerships, licensing deals, or even acquisition interest. Yet, the costs associated with running multicenter trials are substantial and investors should be prepared for potential capital raises to fund ongoing and future studies.
Clinical testing of LP-310 expected to commence in mid-2024
Patient recruitment is underway for Phase 2a multicenter, dose-ranging study
PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the successful completion of its first Site Initiation Visit (SIV) for the Phase 2a trial evaluating LP-310 in the treatment of Oral Lichen Planus (OLP). With clearance received from the central Institutional Review Board (IRB), the Phase 2a trial is set to commence with site qualifications completed and patient recruitment underway.
Lipella’s Phase 2a trial is a multicenter, dose-ranging study involving adult male and female subjects experiencing symptomatic OLP. Approximately 24 subjects will be enrolled across five study sites in the United States. LP-310, Lipella's proprietary liposomal-tacrolimus (LP-10) oral rinse formulation, will be evaluated for safety, tolerability, and efficacy at doses of 0.25 mg, 0.5 mg, and 1.0 mg of tacrolimus. The trial, registered on ClinicalTrials.gov (NCT06233591), aims to address the unmet need for an effective treatment for OLP, a condition that currently lacks FDA-approved therapies.
Participants in the study will undergo screening, treatment, and follow-up phases. During the treatment phase, they will use a 10 mL LP-10 oral rinse for 3 minutes twice a day for 4 weeks, followed by a single post-treatment visit 2 weeks after the last dose. The study is anticipated to conclude in mid-2025.
Dr. Jonathan Kaufman, CEO of Lipella, expressed his enthusiasm, stating, “We are extremely pleased to announce the completion of the Site Initiation Visit for our Phase 2a trial of LP-310. This milestone brings us one step closer to providing a potential treatment for the estimated 6 million Americans affected by OLP, a condition that causes significant pain and has no approved therapies.”
Dr. Michael Chancellor, Chief Medical Officer of Lipella, highlighted the significance of the trial, noting, “OLP presents as a painful oral mucosal disease with no approved therapy. We are optimistic that Lipella's proprietary oral rinse formulation of liposomal tacrolimus offers significant potential in treating OLP while minimizing systemic toxicity. I eagerly anticipate collaborating with the principal investigators to ensure a safe and seamless trial process.”
About Oral Lichen Planus
Oral Lichen Planus (OLP) is a serious and debilitating condition characterized by oral mucosal lesions. It affects millions of individuals worldwide and presents significant challenges in terms of management and treatment. Current therapeutic options are limited, underscoring the critical need for innovative approaches like LP-310 in addressing this unmet medical need.
About Lipella Pharmaceuticals
Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Additionally, Lipella maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella completed its initial public offering in December 2022. For more information, please visit www.lipella.com or LinkedIn.
Forward-Looking Statements
This press release includes certain “forward-looking statements.” All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, future operations, financial position, prospects, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as “may,” “will,” “could,” “continue,” “would,” “should,” “potential,” “target,” “goal,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “predicts,” “expects,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other factors. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax and financial advisors as to legal and related matters concerning the matters described herein.
CONTACT
Dr. Jonathan Kaufman, CEO
Lipella Pharmaceuticals
Info@Lipella.com
1-412-894-1853
Jeff Ramson
PCG Advisory
jramson@pcgadvisory.com
FAQ
What is the purpose of Lipella's Phase 2a trial of LP-310?
When will Lipella's Phase 2a trial of LP-310 start?
How many subjects will participate in Lipella's Phase 2a trial of LP-310?
What doses will be tested in Lipella's Phase 2a trial of LP-310?
When is the Phase 2a trial of LP-310 expected to conclude?
What condition does LP-310 aim to treat in Lipella's Phase 2a trial?
